UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 4, 2016

Versartis, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-36361	26-4106690
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
4200 Bohannon Drive, Suite 250 Menlo Park, California		94025
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (650) 963-8580

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01Other Events. 

On April 4, 2016, the Company announced that Year 2 safety and efficacy data from its ongoing Extension Study of somavaratan in children with moderate growth hormone deficiency (GHD) were presented yesterday in a late-breaker oral presentation at The Endocrine Society’s 98th Annual Meeting & Expo (ENDO 2016) in Boston, MA. A copy of the press release regarding this announcement, titled “Versartis Presents Confirmatory Year Two Data from Ongoing Somavaratan Extension Study at Late-Breaker Session at ENDO Annual Meeting” is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press release dated April 4, 2016, titled “Versartis Presents Confirmatory Year Two Data from Ongoing Somavaratan Extension Study at Late-Breaker Session at ENDO Annual Meeting”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 4, 2016	Versartis, Inc.
	By:	/s/ Joshua T. Brumm
		Joshua T. Brumm
		Chief Financial Officer

INDEX TO EXHIBITS

Exhibit No.	Description
99.1	Press release dated April 4, 2016, titled “Versartis Presents Confirmatory Year Two Data from Ongoing Somavaratan Extension Study at Late-Breaker Session at ENDO Annual Meeting”